3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Sarcoma
5
Small Cell Lung Carcinoma
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Mesothelioma
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Anus Neoplasms
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Testicular Germ Cell Tumor
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Lung Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Adenocarcinoma of Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
regorafenib
2
Doxorubicin
2
Cyclophosphamide
2
Cisplatin
2
tislelizumab
1
tazemetostat
1
sodium thiosulfate
1
entinostat
1
alanosine
1
X-Rays
1
Tamoxifen
1
Specimen Handling
1
Radiotherapy
1
Platinum
1
Magnetic Resonance Spectroscopy
1
Hyperthermic Intraperitoneal Chemotherapy
1
Fentanyl
1
Etoposide
1
Erlotinib Hydrochloride
1
Cytoreduction Surgical Procedures
1
Clinical Trials, Phase II as Topic
1
Celecoxib
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
tislelizumab
×
Sarcoma
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn